• Product NameAcalabrutinib
• Brief DescriptionInhibitors
• Purification99.43%
• Biological ActivityAcalabrutinib, also known as ACP-196, is an orally available inhibitor of Brutons tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
• Target NameBTK inhibitor
• CAS No. 1420477-60-6
• Calculated MW 465.51
• Formulation C26H23N7O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
  Pathways:Angiogenesis
  Receptor:BTK
  Boling pt:
  Melting pt:
  Solubility:DMSO: 93 mg/mL (199.78 mM); Ethanol: 93 mg/mL (199.78 mM);
  Appearance:Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Maly J, et al. Curr Hematol Malig Rep. 2016 Feb;11(1):52-60.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting